TRIDENT BRANDS INCORORATED

FORM 10-Q

For the quarterly period ended ~~August~~May 31, ~~2016~~

2021

PART I	FINANCIAL INFORMATION

Item 1.	Financial Statements (Unaudited)	7 6

	Consolidated Balance Sheets as at ~~August~~May 31, ~~2017~~2021 and November 30, ~~2016~~2020	8 6

	Consolidated Statements of Operations for the three and ~~nine~~six months ended ~~August~~May 31, ~~2017~~2021 and ~~August~~May 31, ~~2016~~2020	9 7
	Consolidated Statements of Changes in Stockholders’ Deficit for the six months ended May 31, 2021 and May 31, 2020	8
	Consolidated Statements of Cash Flows for the ~~nine~~six months ended ~~August~~May 31, ~~2017~~2021 and ~~August~~May 31, ~~2016~~2020	10 9

	Notes to Consolidated ~~Unaudited~~ Financial Statements	11 10

Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	15 17

Item 3.	Quantitative and Qualitative Disclosures about Market Risk	21 23
Item 4.	Controls and Procedures	23

PART II	OTHER INFORMATION
Item 6.	Exhibits	25


~~Item 4~~	~~Controls and Procedures~~	212

~~PART II~~	~~OTHER INFORMATION~~	21

~~Item 6~~	~~Exhibits~~	21Table of Contents

Basis of Presentation

Except where the context otherwise requires, all references in this Quarterly Report on Form 10-Q (“Form 10-Q”) to the “Company”, “we”, “us”, “our”, “Trident” and “Trident Brands” or similar words and phrases are to Trident Brands Incorporated and its subsidiaries, taken together.

In this report, all currency amounts are expressed in thousands of United States (“U.S.”) dollars (“$”), except per share data, unless otherwise stated. Amounts expressed in other than U.S. dollars are noted accordingly. For example, amounts if expressed in Canadian dollars are expressed in thousands of Canadian dollars and preceded by the symbol “Cdn $”.

Forward-Looking Statements

This Form 10-Q contains forward-looking statements which are based on our current expectations and assumptions and involve a number of risks and uncertainties. Generally, forward-looking statements do not relate strictly to historical or current facts and are typically accompanied by words such as “anticipate”, “estimate”, ~~“intend”~~“intend��, “project”, “potential”, “continue”, “believe”, “expect”, “could”, “would”, “should”, “might”, “plan”, “will”, “may”, “predict”, the negatives of such terms, and words and phrases of similar impact and include, but are not limited to references to expected increases in revenues and margins, growth opportunities, the success of new product launches and line extensions, our ability to finance our business, potential strategic investments, business strategies, competitive strengths, goals, references to key markets where we operate and the market for our securities. These forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on certain assumptions and analyses we make in light of our experience and our interpretation of current conditions, historical trends and expected future developments, as well as other factors that we believe are appropriate in the circumstance.

Whether actual results and developments will agree with our expectations and predictions is subject to many risks and uncertainties. Accordingly, there are or will be important factors that could cause our actual results to differ materially from our expectations and predictions. We believe these factors include, but are not limited to, the following:

●

we have a limited operating history with significant losses and expect losses to continue for the foreseeable future;

·	~~there is doubt about our ability~~
	●	we have an urgent need for additional capital to ~~continue as a going concern due to recurring losses from operations, an accumulated deficit and insufficient cash resources on hand to meet~~fund our business ~~objectives, all of which means that~~operations and if we ~~may not~~ae unable to secure needed capital, there will be ~~able to continue operations;~~a material adverse effect on our business and financial condition;

·
	●	we could face intense competition, which could result in lower revenues and higher expenditures and could adversely affect our results of operations;

·
	●	we are governed by only three persons serving as directors and officers which may lead to faulty corporate governance;

·
	●	we must attract and maintain key personnel or our business may fail;

·
	●	we may not be able to secure additional financing to meet our future capital needs due to changes in general economic conditions;

·
	●	our business and operating results could be harmed if we fail to manage our growth or change;

·
	●	we have a limited operating history and if we are not successful in growing our business, then we may have to scale back or even cease our ongoing business operations;

·
	●	if our intellectual property is not adequately protected, then we may not be able to compete effectively and we may not be profitable;

·
	●	if we are the subject of an intellectual property infringement claim, the cost of participating in any litigation could impact our ability to stay in business;

·
	●	we could lose our competitive advantages if we are not able to protect any of our food and nutritional products and intellectual property rights against infringement, and any related litigation could be time-consuming and costly;

Table of Contents

●

if we fail to effectively manage our growth our future business results could be harmed and our managerial and operational resources may be strained;

~~if we fail to effectively manage our growth our future business results could be harmed and our managerial and operational resources may be strained;~~

●

our services may become obsolete and unmarketable if we are unable to respond adequately to rapidly changing technology and customer demands;

·
	●	our failure to appropriately respond to changing consumer preferences and demand for new products or product enhancements could significantly harm product sales and harm our financial condition and operating results;

·
	●	if we do not introduce new products or make enhancements to adequately meet the changing needs of our customers, some of our products could fail in the marketplace, which could negatively impact our revenues, financial condition and operating results;

·
	●	we are affected by laws and governmental regulations with potential penalties or claims, which could harm our financial condition and operating results;

·
	●	since we rely on independent third parties for the manufacture and supply of certain of our products, if these third parties fail to reliably supply products to us at required levels of quality and which are manufactured in compliance with applicable laws, then our financial condition and operating results would be harmed;

·
	●	we may incur material product liability claims, which could increase our costs and harm our financial condition and operating results;

·
	●	unless we can generate sufficient cash from operations or raise additional funds, we may not be able to meet our debt obligations;

·
	●	our customers generally are not obligated to continue purchasing products from us;

·
	●	if we do not manage our supply chain effectively, our operating results may be adversely affected;

·
	●	our stock price may be volatile, which may result in losses to our shareholders;

·
	●	our common shares are thinly traded and our shareholders may be unable to sell at or near ask prices, or at all;

●

the market price for our common stock is particularly volatile given our status as a relatively small and developing company, which could lead to wide fluctuations in our share price. Our shareholders may be unable to sell your common stock at or above their purchase price if at all, which may result in substantial losses;

·
	●	we do not anticipate paying any cash dividends to our common shareholdersand as a result shareholders may only realize a return when the shares are sold;

·
	●	we are ~~listed~~quoted on the OTCQB quotation system and our common stock is subject to “penny stock” rules which could negatively impact our liquidity and our shareholders’ ability to sell their shares;

·
	●	volatility in our common share price may subject us to securities litigation;

·
	●	the elimination of monetary liability against our directors, officers and employees under Nevada law and the existence of indemnification rights of our directors, officers and employees may result in substantial expenditures by our company and may discourage lawsuits against our directors, officers and employees; ~~and~~

·
	●	our business is subject to changing regulations related to corporate governance and public disclosure that have increased both our costs and the risk of ~~noncompliance.~~noncompliance; and

	●	The recent coronavirus outbreak could have an adverse effect on our business.

		Concerns remain about the global outbreak of a novel strain of coronavirus (COVID-19). The virus spread rapidly across the globe, including the U.S. The pandemic had an unprecedented impact on the U.S. economy as federal, state and local governments reacted to this public health crisis, which has created significant uncertainties. These uncertainties include, but are not limited to, the potential adverse effect of the pandemic on the economy, our customers and supply chain.

		Consumer fear about becoming ill with the virus and recommendations and/or mandates from federal, state and local authorities to avoid large gatherings of people or self-quarantine may continue. The extent of the impact of the pandemic on our business and financial results will depend largely on future developments, including the duration of the outbreak within the U.S., the impact on capital and financial markets and the related impact on consumer confidence and spending, all of which are highly uncertain and cannot be predicted. This situation is changing rapidly, and additional impacts may arise that we are not aware of currently.

Table of Contents

Consequently all forward-looking statements made herein are qualified by these cautionary statements and there can be no assurance that our actual results or the developments we anticipate will be realized. The foregoing factors should not be construed as exhaustive and should be read in conjunction with the other cautionary statements that are included in this report.

Corporate Legal Structure and Related Matters

Trident Brands Incorporated has ~~five~~four legal subsidiaries, as detailed below.

Trident Sports Nutrition Inc. is 100% owned by Trident Brands and is organized to deliver shelf ready product solutions in the ~~sports~~active nutrition and dietary supplement segment to leading retailers for private label and ~~captive label~~control brand programs.

Brain Armor Inc. is ~~85%~~70.5% owned by Trident Brands and is organized to develop, market and sell a portfolio of DHA supplements under the Brain Armor® brand targeted at the cognitive health and performance segment.

~~Sports Nutrition Product Inc.~~ ~~(DBA Everlast Nutrition)~~

Trident Health is 100% owned by Trident Brands and ~~holds an exclusive license to market and sell products in the nutritional food and supplement category under the Everlast® brand.~~

is currently inactive.

Trident Brands Canada Ltd. is 100% owned by Trident Brands Incorporated and holds various banking facilities, and licenses associated with the manufacturing, importation and sale of natural health and nutrition products in Canada.

~~Trident Brands International Ltd.~~ ~~is 100% owned by Trident Brands and was organized to handle the company’s international operations and sub-license trademarks and/or products in international markets.~~

The Company’s administrative office is located at 200 South Executive Drive, Suite 101, Brookfield, Wisconsin, 53005 and its fiscal year end is November 30th.

The Company has authorized capital of 300,000,000 common shares with a par value of $0.001 per share. ~~31,000,000~~32,311,887 common shares were issued and outstanding as of ~~August~~May 31, ~~2017~~2021 and 32,311,887 as of ~~October 16, 2017.~~

July 20, 2021.

Table of Contents

ITEM 1. FINANCIAL STATEMENTS

The unaudited financial statements for the quarter ended ~~August~~May 31, ~~2017~~2021 immediately follow.

TRIDENT BRANDS INCORPORATED

Consolidated Balance Sheets

(Unaudited)

As of As of
August 31, 2017 November 30, 2016
ASSETS

Current Assets
Cash $ 4,130,378 $ 1,527,624
Restricted Cash 250,000 -
Accounts Receivable 661,799 53,053
Inventory 274,367 231,221
Prepaid 210,748 67,332
Total Current Assets 5,527,292 1,879,230

Fixed Assets-Furniture & Fixtures, net 28,029 -
Intangible Assets - Licenses, net 2,200,000 2,425,000

TOTAL ASSETS $ 7,755,321 $ 4,304,230

LIABILITIES & STOCKHOLDERS' DEFICIT

Current Liabilities
Accounts Payable $ 1,322,818 $ 106,612
Accrued Liability 1,150,958 431,178
Loan Payable - Third Party, net of discount $0 and $8,812, respectively - 191,188
Total Current Liabilities 2,473,776 728,978

Convertible Debt, net of discount $2,220,465 and $1,285,836, respectively 8,579,535 5,114,164

Total Liabilities 11,053,311 5,843,142

Stockholders' Deficit
Common stock, $0.001 par value, 300,000,000 shares authorized;
31,000,000 shares issued and outstanding as of August 31, 2017 and November 30, 2016 31,000 31,000
Additional paid-in capital 6,922,854 5,431,976
Non-Controlling Interest in Subsidiary (95,183 ) (65,786 )
Accumulated Deficit (10,156,661 ) (6,936,102 )
Total Stockholders' Deficit (3,297,990 ) (1,538,912 )

TOTAL LIABILITIES & STOCKHOLDERS' DEFICIT $ 7,755,321 $ 4,304,230

	As of			As of
	May 31,			November 30,
	2021			2020

ASSETS

Current Assets
Cash and Cash Equivalents	$	131,361		$	88,007
Accounts Receivable, net of allowance of $157,526 and $155,186 respectively		71,505			63,784
Inventory, net of reserves of $195,264 and $195,264 respectively		1,107,587			1,219,567
Prepaid and other current assets		68,907			155,179

Total Current Assets		1,379,360			1,526,537

Intangible Assets, net		400,000			400,000

TOTAL ASSETS	$	1,779,360		$	1,926,537

LIABILITIES & STOCKHOLDERS’ DEFICIT

Current Liabilities
Accounts Payable	$	421,062		$	429,009
Accrued Liabilities		8,297,295			7,480,846

Total Current Liabilities		8,718,357			7,909,855

PPP Loan Payable		135,165			135,165
Convertible Debt, net of discount of $0 and $0, respectively		22,300,000			22,300,000

Total Liabilities		31,153,522			30,345,020

Stockholders’ Deficit

Common stock, $0.001 par value, 300,000,000 shares authorized; 32,311,887 shares issued and outstanding as of May 31, 2021 and November 30, 2020		32,312			32,312
Additional paid-in capital		11,458,630			11,458,630
Non-Controlling Interest in Subsidiary		(161,237	)		(387,147	)
Accumulated Deficit		(40,703,867	)		(39,522,278	)

Total Stockholders’ Deficit		(29,374,162	)		(28,418,483	)

TOTAL LIABILITIES & STOCKHOLDERS’ DEFICIT	$	1,779,360		$	1,926,537

See Notes to Unaudited Consolidated Financial Statements

Table of Contents

TRIDENT BRANDS INCORPORATED

Consolidated Statements of Operations ~~(unaudited)~~

Three Months Three Months Nine Months Nine Months
Ended Ended Ended Ended
August 31, 2017 August 31, 2016 August 31, 2017 August 31, 2016

Revenues $ 3,277,655 $ 17,028 $ 3,305,644 $ 241,053

Cost of Sales 3,117,150 9,388 3,132,266 135,364

Gross Profit 160,505 7,640 173,378 105,689

General, Selling & Administrative Expenses (908,378 ) (502,659 ) (2,375,051 ) (1,755,774 )

Loss from Operations (747,873 ) (495,019 ) (2,201,673 ) (1,650,085 )

Other Income (Expenses)
Interest Expense (489,593 ) (79,269 ) (1,048,283 ) (351,353 )
Total Other Income (Expenses) (489,593 ) (79,269 ) (1,048,283 ) (351,353 )

Net Loss $ (1,237,466 ) $ (574,288 ) $ (3,249,956 ) $ (2,001,438 )

Net loss attributable to Trident (1,228,122 ) (566,582 ) (3,220,559 ) (1,990,807 )
Net loss attributable to Non-Controlling Interests (9,344 ) (7,706 ) (29,397 ) (10,631 )

Loss per share - Basic and diluted $ (0.04 ) $ (0.02 ) $ (0.10 ) $ (0.07 )

Weighted average number of common
shares outstanding - Basic and diluted 31,000,000 31,000,000 31,000,000 30,596,364

(Unaudited)

	Three Months			Three Months			Six Months			Six Months
	Ended			Ended			Ended			Ended
	May 31,			May 31,			May 31,			May 31,
	2021			2020			2021			2020

Revenues, net	$	46,243		$	244,102		$	190,291		$	405,987
Cost of Sales		24,580			167,240			103,368			252,169
Gross Profit		21.663			76,862			86,923			153,818

General & Administrative Expenses		(537,978	)		(1,119,556	)		(942,262	)		(2,433,290	)
Loss from Operations		(516,315	)		(1,042,694	)		(855,339	)		(2,279,472	)

Other Income (Expenses)
Interest Expense, net		(200,008	)		(1,001,119	)		(400,341	)		(2,447,807	)
Gain on Debt Forgiveness		-			10,000			-			10,000
Derivative loss		-			(8,028,629	)		-			(9,601,342	)
Total Other Income (Expenses)		(200,008	)		(9,019,748	)		(400,341	)		(12,039,149	)

Net Loss	$	(716,323	)	$	(10,062,442	)	$	(1,255,680	)	$	(14,318,621	)

Net loss attributable to Trident		(646,092	)		(10,035,750	)		(1,181,590	)		(14,262,178	)
Net loss attributable to Non-Controlling Interests		(70,231	)		(26,692	)		(74,090	)		(56,443	)

Loss per share - Basic and diluted	$	(0.02	)	$	(0.31	)	$	(0.04	)	$	(0.44	)

Weighted average number of common shares outstanding - Basic and diluted		32,311,887			32,311,887			32,311,887			32,311,887

See Notes to Unaudited Consolidated Financial Statements

Table of Contents

TRIDENT BRANDS INCORPORATED

Consolidated Statements of ~~Cash Flows (unaudited)~~

Nine Months Nine Months
Ended Ended
August 31, 2017 August 31, 2016
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss $ (3,249,956 ) $ (2,001,438 )
Adjustments to reconcile net loss to net cash used in operating activities:
Amortization of debt discount 540,850 190,245
Amortization of license 225,000 200,000
Stock option expense 24,211 101,565
Changes in operating assets and liabilities:
Accounts Receivable (608,746 ) (138,763 )
Prepaid expenses (143,416 ) 646
Inventory (43,146 ) (162,418 )
Accounts payable and accrued liabilities 1,935,986 1,176,761
Cash used in operating activities (1,319,217 ) (633,402 )

CASH FLOWS FROM INVESTING ACTIVITIES
Restricted Cash (250,000 ) -
Purchase of Fixed Assets (28,029 ) -
Cash used in investing activities (278,029 ) -

CASH FLOWS FROM FINANCING ACTIVITIES
Proceeds on loan payable - related party - 200,000
Principal payments on loan payable - third party (200,000 ) -
Proceeds on loan payable - third party - 250,000
Proceeds on convertible debt 4,400,000 -
Cash provided by financing activities 4,200,000 450,000

Net change in cash 2,602,754 (183,402 )

Cash at beginning of period 1,527,624 187,886

Cash at end of period $ 4,130,378 $ 4,484

NON-CASH TRANSACTIONS
Beneficial conversion features $ 1,466,667 $ -
Common stock issued for asset acquisition - 2,700,000
Relative fair value of warrants recorded as debt discount - 78,776

Supplemental disclosure of cash flow information:

Cash paid for:
Income taxes $ - $ -
Interest $ 20,083 $ -

Changes in Stockholders’ Deficit

From the quarter ended May 31, 2021 and May 31, 2020

(Unaudited)

			Common		Additional						Non-
	Common		Stock		Paid-in			Accumulated			Controlling
	Stock		Amount		Capital			Deficit			Interest			Total

Balance, November 30, 2019		32,311,887	$	32,312	$	9,945,488		$	(34,225,630	)	$	(288,603	)	$	(24,536,433	)

APIC reclassified to derivative liability		-		-		(3,981,220	)		-			-			(3,981,220	)
Net loss, February 29, 2020		-		-		-			(4,226,428	)		(29,751	)		(4,256,179	)

Balance, February 29, 2020		32,311,887	$	32,312	$	5,964,268		$	(38,452,058	)	$	(318,354	)	$	(32,773,832	)
Net loss, May 31, 2020									(10,035,750	)		(26,692	)		(10,062,442	)
Balance, May 31, 2020		32,311,887		32,312		5,964,268			(48,487,808	)		(345,046	)		(42,836,274	)

Balance, November 30, 2020		32,311,887	$	32,312	$	11,458,630		$	(39,522,278	)	$	(387,147	)	$	(28,418,483	)

Net loss, February 28, 2021		-		-		-			(539,498	)		(3,859	)		(539,357	)

Balance, February 28, 2021		32,311,887	$	32,312	$	11,458,630		$	(40,057,776	)	$	(391,006	)	$	(28,957,840	)

NCI Investment in Brain Armor									-			300,000			300,000
Net loss, May 31, 2021									(646,091	)		(70,231	)		(716,323	)
Balance May 31, 2021		32,311,887		32,312		11,458,630			(40,703,867	)		(161,237	)		(29,374,163	)

See Notes to Unaudited Consolidated Financial Statements

Table of Contents

TRIDENT BRANDS INCORPORATED

Consolidated Statements of Cash Flows

(Unaudited)

	Three Months			Three Months
	Ended			Ended
	May 31,			May 31,
	2021			2020

CASH FLOWS FROM OPERATING ACTIVITIES

Net loss	$	(1,255,680	)	$	(14,318,621	)
Adjustments to reconcile net loss to net cash used in operating activities:
Amortization of debt discount		-			1,339,440
Depreciation expense		-			4,191
Derivative (gain)/loss		-			9,601,342
Provision for bad debts		2,340			-

Changes in operating assets and liabilities:
Accounts Receivable		(10,061	)		69,696
Prepaid expenses		86,272			(94,482	)
Inventory		111,980			247,852
Accounts payable and accrued liabilities		808,503			1,266,543

*Cash used in operating activities*		(256,646	)		(1,807,673	)

CASH FLOWS FROM FINANCING ACTIVITIES

Proceeds from PPP loan		-			135,165
Proceeds from convertible debt		-			936,168
Proceeds from NCI investment in Brain Armor		300,000			-

Cash provided by financing activities		300,000			1,071,333

NET CHANGE IN CASH AND CASH EQUIVALENTS		43,354			(736,340	)

CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD		88,007			1,013,674

CASH AND CASH EQUIVALENTS AT END OF PERIOD	$	131,361		$	277,334

Supplemental disclosure of cash flow information:

Cash paid for:
Income taxes	$	-		$	-
Interest	$	-		$	-

See Notes to Unaudited Consolidated Financial Statements

Table of Contents

TRIDENT BRANDS INCORPORATED

Notes to Consolidated Financial Statements

~~August~~

May 31, ~~2017~~

2021

(Unaudited)

NOTE 1. ORGANIZATION AND DESCRIPTION OF BUSINESS

Trident Brands Incorporated ~~(f/k/a Sandfield Ventures Corp.)~~ (“we”, “our”, “the Company”) was incorporated under the laws of the State of Nevada on November 5, 2007. ~~The Company was formed to engage in the acquisition, exploration and development of natural resource properties.~~

The Company is ~~now~~ focused on the development of high growth branded and private label consumer products and ingredients within the nutritional supplement, life sciences and food and beverage categories. The Company is in its early growth stage and has transitioned out of its shell status with the Super-8 filing at the end of August, 2014. Activities to date have focused on capital formation, organizational development and execution of its branded and private label consumer products and ingredients business plan.

NOTE 2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Basis of Presentation

The accompanying unaudited interim ~~consolidated~~ financial statements of ~~Trident Brands Incorporated~~the Company have been prepared in accordance with accounting principles generally accepted in the United States of America and the rules of the Securities and Exchange Commission, and should be read in conjunction with the audited ~~consolidated~~ financial statements and notes thereto contained in ~~Trident’s~~the Company’s Form 10-K filed with SEC. In the opinion of management, all adjustments, consisting of normal recurring adjustments, necessary for a fair presentation of financial position and the results of operations for the interim periods presented have been reflected herein. The results of operations for interim periods are not necessarily indicative of the results to be expected for the full year. Notes to the ~~consolidated~~ financial statements which would substantially duplicate the disclosure contained in the audited ~~consolidated~~ financial statements for fiscal ~~2016~~2020 as reported in the Form 10-K have been omitted.

~~Restricted Cash~~

~~Restricted cash~~Use of ~~$250,000~~Estimates

The preparation of financial statements in conformity with U.S. GAAP requires the Company to make estimates and judgments that affect the reported amounts of assets and liabilities, revenues and expenses, and related disclosures of contingent assets and liabilities. These estimates and judgments are based on historical information, information that is currently available to the Company and on various other assumptions that the Company believes to be reasonable under the circumstances. Actual results could differ from those estimates. The ultimate impact from COVID-19 on the Company’s operations and financial results during 2020 will depend on, among other things, the ultimate severity and scope of the pandemic, the pace at which governmental and private travel restrictions and public concerns about public gatherings will ease, the rate at which historically large increases in unemployment rates will decrease, if at all, and whether, and the speed with which the economy recovers. We are not able to fully quantify the impact that these factors will have on our financial results during 2021 and beyond, but expect developments related to COVID-19 to materially affect the Company’s financial performance in 2021.

Customer Concentration

Two customers accounted for 19.9% and 11.5% of total revenue for the six month period ended May 31, 2021 compared to four customers accounting for 22.3%, 17.7%, 13.0% and 10.2% for the 12 month period ended November 30, 2020. Two customers accounted for 39.4% and 29.2% of total accounts receivable as of ~~August~~May 31, ~~2017 represents cash held~~2021 compared to three customers accounting for 16.9%, 15.9% and 11.9% as of November 30, 2020.

Table of Contents

Fair Value of Financial Instruments

The Company measures its financial assets and liabilities in accordance with the requirements of FASB ASC 820, “Fair Value Measurements and Disclosures”. ASC 820 clarifies the definition of fair value, prescribes methods for measuring fair value, and establishes a ~~trust account. The funds have been set aside~~fair value hierarchy to classify the inputs used in measuring fair value as follows:

Level 1 – Quoted prices are available in active markets for identical assets or liabilities as of the reporting date. Active markets are those in which transactions for the ~~acquisition~~asset or liability occur in sufficient frequency and volume to provide pricing information on an ongoing basis. Level 1 primarily consists of ~~StreamPak Ltd (see Note 9 regarding subsequent events)~~financial instruments such as exchange-traded derivatives, marketable securities and listed equities.

Level 2 – Pricing inputs are other than quoted prices in active markets included in level 1, which are either directly or indirectly observable as of the reported date and includes those financial instruments that are valued using models or other valuation methodologies. These models are primarily industry-standard models that consider various assumptions, including quoted forward prices for commodities, time value, volatility factors, and current market and contractual prices for the underlying instruments, as well as other relevant economic measures.

Substantially all of these assumptions are observable in the marketplace throughout the full term of the instrument, can be derived from observable data or are supported by observable levels at which transactions are executed in the marketplace. Instruments in this category generally include non-exchange-traded derivatives such as commodity swaps, interest rate swaps, options and collars.

Level 3 – Pricing inputs include significant inputs that are generally less observable from objective sources. These inputs may be used with internally developed methodologies that result in management’s best estimate of fair value.

The carrying value of certain on-balance-sheet financial instruments approximated their fair values due to ~~cover legal~~the short-term nature of these instruments. These financial instruments include cash and ~~other related costs.~~

cash equivalents, accounts receivable, accounts payable and note payable. The fair value of the Company’s long-term debt is estimated based on current rates that would be available for debt of similar terms which is not significantly different from its stated value. As of May 31, 2021 the Company did not have any financial assets or liabilities measured and recorded at fair value on the Company’s consolidated balance sheets on a recurring basis.

~~Customer Concentration~~Recent Accounting Pronouncements

The Company has ~~one major customer~~evaluated recent accounting pronouncements through the date the financial statements were issued and filed with the Securities and Exchange Commission and believe that ~~accounted for approximately 98% and $3,240,318 of sales for~~there are none that will have a material impact on the ~~nine month period ended August 31, 2017 and 97% of the accounts receivable.~~

~~Reclassification~~

~~Certain amounts in the 2016~~Company’s financial statements.

NOTE 3. GOING CONCERN

The accompanying interim consolidated financial statements have been ~~reclassified to conform to the 2017 financial presentation. These reclassifications have no impact on net loss.~~

~~NOTE 3. LIQUIDITY~~

~~On September 26, 2016,~~prepared assuming that the Company ~~completed~~will continue as a ~~long term financing with a non-US institutional investor, receiving proceeds~~going concern, which contemplates realization of ~~$4,100,000~~assets and ~~subsequently $4,400,000 on May 9, 2017 through~~ the ~~issuance~~satisfaction of ~~secured convertible promissory notes. The investor has agreed to make additional investments at the Company’s request of up to $1,500,000 ($10,000,000~~liabilities in the ~~aggregate).~~ normal course of business within one year after the date the consolidated financial statements are issued. In accordance with Financial Accounting Standards Board, or the FASB, Accounting Standards Update No. 2014-15, Presentation of Financial Statements - Going Concern (Subtopic 205-40), our management evaluates whether there are conditions or events, considered in aggregate, that raise substantial doubt about our ability to continue as a going concern within one year after the date that the financial statements are issued.

As of ~~August~~May 31, ~~2017,~~2021, the Company had ~~$4,380,378~~$131,361 in cash and a working capital deficit of $7,338,997. The Company also has ~~access~~generated losses and has an accumulated deficit as of May 31, 2021. These factors raise substantial doubt about the ability of the Company to ~~$1,500,000 available~~continue as a going concern. Unless Management is able to obtain additional financing, the Company may not be able to meet its funding requirements during the next 12 months. The financial statements do not include any adjustments that might result from the ~~investor. The Company feels~~outcome of this ~~represents substantial liquid resources (cash & available financing), sufficient to meet the Company’s obligations for the next twelve months.~~

uncertainty.

Table of Contents

NOTE 4. WARRANTS AND OPTIONS

The total outstanding stock options as of August 31, 2017 are 2,025,000. The Company uses the Black-Scholes model to value the stock options at $535,021. For the period ended August 31, 2017, the Company expensed $24,211 as compensation expense compared to $101,565 in the previous year. Following are the assumptions used for the shares vested 12, 24 and 36 months from the date of issuance: Discount rate 0.9%, 1.29%, 1.29%; Volatility 68.35%, 67.35%, 65.50%; and Term 3.0, 3.5, 4.0.

The following table represents stock option activity for the six month period ended ~~August~~May 31, ~~2017:~~

~~TRIDENT BRANDS INCORPORATED~~

~~Notes to Consolidated Financial Statements~~

~~August~~2021:

	Number of Options		Weighted Average Exercise Price		Contractual Life in Years		Intrinsic Value
Outstanding - November 30, 2020		1,832,500	$	0.40		2.02
Exercisable - November 30, 2020		1,832,500	$	0.40		2.02	$	-0-
Granted	-0-
Exercised or Vested	-0-
Forfeited or Expired	-0-
Outstanding - May 31, 2021		1,832,500	$	0.40		1.52
Exercisable - May 31, 2021		1,832,500	$	0.40		1.52	$	-0-

As of May 31, ~~2017~~

~~(Unaudited)~~

Number of
Options

Weighted
Average
Exercise Price

Contractual Life
in Years

Intrinsic
Value

Outstanding - November 30, 2016 2,358,333 $ 0.96 2.51

Exercisable - November 30, 2016 1,666,667 $ 1.17 2.43

Granted -0- $ 0.0

Exercised or Vested -0-

Cancelled or Expired 333,333

Outstanding - August 31, 2017 2,025,000 $ 0.96 1.68

Exercisable - August 31, 2017 2,025,000 $ 0.96 1.68 $8,417

~~The total~~2021, the Company has no outstanding warrants. All the outstanding warrants as of August 31, 2017 are 225,000. The exercise price of the warrants are $1.35 with a term of 3 years and vested immediately. The Company uses the Black-Scholes model to value the warrants. Following are the assumptions used: Discount rate .9%; Volatility 76.25% and 77.30% respectively.

~~The following table represents warrant activity for the period ended August 31, 2017:~~

Number of
Warrants

Weighted
Average
Exercise Price

Contractual Life
in Years

Intrinsic
Value

Outstanding – November 30, 2016 225,000 $ 1.35 2.21

Exercisable - November 30, 2016 -0-

Granted -0-

Exercised or Vested -0-

Cancelled or Expired -0-

Outstanding – August 31, 2017 225,000 $ 1.35 1.45 $ 0

have expired.

NOTE 5. ~~RELATED PARTY TRANSACTIONS~~

~~The Company neither owns nor leases any real or personal property. The Company is paying a director $750 per month rent for use of office space and services.~~

~~NOTE 6. LOAN PAYABLE – THIRD PARTY~~

On February 29, 2016, the Company entered into a Securities Purchase Agreement with CIC whereby the Company received proceeds of $200,000 on March 4, 2016 in return for a $200,000 secured promissory note due 12 months from the issuance date, bearing interest at the rate of 10% per annum, plus 100,000 warrants to purchase common shares of the Company at an exercise price of $1.35 per share for three years from the date of issue. The loan was paid back on March 3, 2017. The remaining debt discount of $8,812 was fully amortized to interest expense during the nine months ended August 31, 2017.

~~TRIDENT BRANDS INCORPORATED~~

~~Notes to Consolidated Financial Statements~~

~~May 31, 2017~~

~~(Unaudited)~~

~~NOTE 7.~~ CONVERTIBLE ~~NOTE~~

DEBT

On January 29, 2015, the Company entered into a securities purchase agreement with a non-US institutional investor whereby it agreed to sell an aggregate principal amount of $2,300,000 of senior secured convertible debentures, convertible into shares of the ~~company’s~~Company’s common stock.

The Company received $1,800,000 of the funds from the transaction on February 5, 2015. The balance of $500,000 was received on May 14, 2015.

These convertible notes were subsequently acquired by Fengate Trident, LP (‘Fengate”) on April 28, 2017.

The convertible debentures are convertible into shares of the Company’s common stock at an initial conversion price of $0.71 per share, for an aggregate of up to 3,239,437 shares. The debentures originally accrued interest at 6% per annum. On September 26, 2016 the Company entered into an amendment agreement related to these convertible debentures whereby the applicable interest rate was increased from 6% to 8% and provisions added to allow the investor to transfer, sell or hypothecate the convertible notes subject to applicable securities laws. The maturity date of the notes was also extended through September 30, 2019.

We considered ASC Topic 470-50, Debt Modifications and Extinguishments, and determined that the modification was not deemed substantial.

Due to the note being convertible to common shares of the Company, a beneficial conversion feature analysis was performed. The intrinsic value of the conversion feature was $647,888 which was recognized as debt discount. As of ~~August 31,~~November 30, 2017, the full amount of the debt discount has been amortized.

On September 26, 2016, the Company entered into a securities purchase agreement with a non-US institutional investor, pursuant to which, in consideration for proceeds of $4,100,000, the Company issued a secured convertible promissory note in the amount of $4,100,000. Pursuant to the securities purchase agreement, the investor has agreed, from time to time after January 1, 2017, to make additional investments at the Company’s request of up to $5,900,000 ($10,000,000 in the aggregate) in one or more tranches of not less than one tranche during any 60 day period. The funding of any tranche under the agreement (other than the first $4,100,000 which has been funded) is subject to the mutual agreement of the parties as to the use of funds.

$5,900,000. On May 9, 2017, the Company received the second tranche of funding with proceeds of $4,400,000 and on May 16, 2018 the third tranche of $1,500,000 for a total investment by the investor of ~~$8,500,000. Under the terms of the securities purchase agreement, the Company has an additional $1,500,000 of available funding.~~

$10,000,000.

The Company ~~intends to use~~used the proceeds of the secured convertible note for general working capital purposes including ~~without limitation,~~ settlement of accounts payable and repayment of mature loans.

Table of Contents

In consideration of each advance made by the investor pursuant to the securities purchase agreement, the Company ~~will issue~~issued to the investor a convertible promissory note of equal value, maturing ~~three years after issuance,~~on September 30, 2019, and bearing interest at the rate of 8% per annum. Each note ~~will be~~is secured in first priority against the present and after acquired assets of the Company and ~~will be~~is convertible in whole or in part at the option of the holder into common shares of the Company at a conversion price of $0.60 per share, for an aggregate of up to ~~14,166,667~~16,666,667 shares.

These convertible notes were subsequently acquired by Fengate on April 28, 2017.

Due to the notes being convertible to common shares of the Company, a beneficial conversion feature analysis was performed. The intrinsic value of the conversion feature of the notes amounted to ~~$2,833,334~~$3,333,334 and was recognized as a debt discount. As of ~~August 31, 2017, $612,869~~November 30, 2020, $3,333,334 of the debt discount was amortized to interest of which ~~$532,038~~$334,988 was amortized during the current ~~9 month period and $80,831~~year compared to $855,987 in the prior year. As of November 30, 2020, the debt discount was fully amortized.

On November 30, 2018 the Company and Fengate entered into a Securities Purchase Amendment Agreement (‘SPA’) pursuant to which the Company has agreed to issue to Fengate additional convertible promissory notes (collectively, the “2018 and 2019 Convertible Notes”) of up to $10,000,000, subject to certain terms and conditions. Each portion of the principal amount advanced pursuant to the SPA will bear interest at the rate of twelve percent (12%) per annum and will be payable monthly in arrears to Fengate. Outstanding principal and interest will continue to be secured by the general security agreement dated September 26, 2016, which forms a part of the Agreement. The ~~unamortized~~holder of the note may also elect from time to time to convert all or a portion of the outstanding principal and interest into common shares of the Company at a 25% discount ~~is $2,220,465.~~

to the average closing price of the common shares during the 10 trading days immediately prior to the applicable conversion date.

On November 30, 2018 the Company received the first tranche of funding with proceeds of $3,400,780. The 2^nd tranche of $2,804,187 was received on April 13, 2019. The 3^rd tranche of $3,795,033 less $936,168 withheld for interest payments up to and including June 30, 2020 was received on November 6, 2019. On March 5, 2020, the 2018 and 2019 Convertible Notes were amended to increase the amount of the 3rd tranche by $936,168 representing the amount previously withheld as interest payment. The withheld interest was subsequently received on March 12, 2020.

The Company analyzed the embedded conversion option on the convertible notes for derivative accounting consideration under ASC 815-15 “Derivatives and Hedging” and determined that the conversion option ~~should be classified~~on the 2018 Convertible Note qualified for derivative accounting. The Company used the Black-Scholes model to value the embedded conversion option at $892,000 on the issuance date of November 30, 2018, $1,911,256 on the issuance date of April 13, 2019 and $1,696,933 on the issuance date of November 6, 2019.The assumptions used were a discount rate of 2.80%, 1.96% and 1.96%; volatility rate of 79.57%, 104.70% and 107.3%; and a term of 1.50, 1.13 and 0.57 years respectively. The fair values of the embedded conversion options were recorded as ~~equity.~~

~~TRIDENT BRANDS INCORPORATED~~

~~Notes to Consolidated Financial Statements~~

~~May 31, 2017~~

~~(Unaudited)~~

~~NOTE 8. INTANGIBLE ASSETS~~

debt discount and were amortized over the term of the 2018 and 2019 Convertible Notes. Amortization of debt discount for the years ended November 30, 2020 and 2019 was $1,885,587 and $1,857,295, respectively. The unamortized discount as of November 30, 2020 is $0.

On January ~~22, 2015, pursuant to a Deed of Assignment dated effective January 20, 2015,~~9, 2020 the Company and Fengate entered into an ~~Emulsion Supply~~Amendment to Convertible Promissory Notes Agreement ~~with Oceans Omega LLC which represents~~to amend the ~~rights acquired pursuant~~terms of the convertible notes issued on February 5, 2015 (US$1,800,000), May 14, 2015 (US$500,000), September 26, 2016 (US$4,100,000), May 9, 2017 (US$4,400,000) and May 16, 2018 (US$1,500,000) (collectively the “2016 Convertible Notes”). Pursuant to the ~~Deed~~Amendment, Fengate has agreed to convert all of ~~Assignment. The Emulsion Supply Agreement provides~~the 2016 Notes on or before the earlier to occur of (i) the maturity date of the 2016 Convertible Notes and (ii) the Company ~~with the non-exclusive right~~raising new equity investment of not less than US$2,000,000, on terms mutually acceptable to Fengate and license (without the right to sublicense) to purchase, market, promote, sell and distribute Oceans Omega LLC’s omega-3 emulsions for use in the development, production, processing, manufacture and sale of food and beverages and exclusive rights to purchase, market, promote, sell and distribute Oceans Omega emulsions for meats, for human or animal consumption. On January 6, 2016 the Company ~~issued 3,000,000 shares~~(subject to ~~mark the closing~~Fengate’s regulatory considerations). Conversion of the Deed of Assignment and the Emulsion Supply Agreement, which did not specify the amount of consideration payable by the Company when they were executed on January 20, 2015. The consideration payable was subsequently established by the parties2016 Notes will occur in a single conversion transaction at a ~~market value of $2,700,000 and common shares issued as compensation based on~~price that is equal to a 25% discount to the average closing price of the Company’s common ~~shares as quoted~~stock for the 10 trading days immediately prior to the conversion date, with the exact structure of the conversion to be determined by the parties. On June 3, 2020 the maturity date was extended from May 31 to December 31, 2020. The Amendment also extended the maturity date of the 2018 and 2019 Convertible Notes to December 1, 2021.

Table of Contents

The Company analyzed the embedded conversion option on the ~~OTC Markets quotation systems on~~amended “2016 Convertible Notes” for derivative accounting consideration under ASC 815-15 “Derivatives and Hedging” and determined that the conversion option qualified for derivative accounting. On January ~~6, 2016.~~9, 2020 the Company used the Black-Scholes model to value the embedded conversion options at $7,965,083. The ~~value~~assumptions used were a discount rate of ~~the license is~~1.96%, volatility rate of 148.8%; and a term of 0.39 years respectively. The modification resulted in $3,981,221 of APIC previously recorded for beneficial conversion feature of these convertible notes being amortized over the remaining contractual life which is 9 years. As of August 31, 2017, the net value of the license was $2,200,000 after amortizing $500,000. Amortization expense for the nine months ended August 31, 2017 and 2016 was $225,000 and $200,000, respectively.

~~NOTE 9. SUBSEQUENT EVENTS~~

reclassified as derivative liability.

On ~~September 12, 2017~~November 30, 2020, the Company entered into a ~~note purchase agreement with Fengate Trident LP pursuant to which, in consideration for~~fourth amendment of the ~~issuance of 811,887 of our common shares~~2016 Convertible Notes and the 2018 and 2019 Convertible Notes wherein the Company will issue to Fengate ~~we purchased outstanding secured convertible promissory notes~~29,432,320 shares of ~~Mycell Technologies LLC having an aggregate balance due and payable~~Company Preferred Stock (representing $17,659,392 of ~~$511,141 in~~ principal and ~~$94,526 in~~ interest accrued as at September 12, 2017. The purchased notes, which were originally issued to LPF (MCTECH) Investment Corp. on January 22, 2016, February 5, 2016, and May 19, 2016, bear simple interest on unpaid principalconverted into Preferred Stock at the rate of ~~ten percent~~$0.60 per ~~annum. The outstanding principal~~share), in full and complete satisfaction of (i) all amounts owing under the 2016 Convertible Notes through November 30, 2020 (including accrued interest thereon) and (ii) all accrued interest on the 2018 and 2019 Convertible Notes through November 30, 2020. The conversion is ~~convertible~~expected to occur during the third fiscal quarter of 2021. The 2018 and 2019 Convertible Notes were further amended to (i) eliminate the conversion feature of such notes, (ii) provide for a simple interest rate of 8% per annum, with the first 2 years of interest payable at maturity of the 2018 and 2019 Convertible Notes and the last three years of interest payable quarterly beginning May 31, 2023; and (iii) extend the maturity of such notes until November 30, 2025. Pursuant to this amendment, all notes no longer qualified for derivative accounting. As such, the value of the embedded conversion options of all notes of $5,494,363 was credited to additional paid in capital. The issuance of the Preferred Shares is subject to stockholder approval.

We considered ASC Topic 470-50, Debt Modifications and Extinguishments in connection with the amendment of the interest rate and maturity date of the 2018 and 2019 Convertible Notes and determined that the modification would be considered a debt extinguishment. The unamortized discount of $1,092,295 at the ~~option~~date of amendment was recognized as a loss on debt extinguishment for the year ended November 30, 2020.

On June 30, 2021, the Board of Directors of the ~~note holder into securities~~Company, unanimously consented to amend its Articles of ~~Mycell. We issued~~Incorporation to among other things authorize 29,432,320 shares of Preferred Stock, $0.001 par value.

NOTE 6. PAYCHECK PROTECTION PROGRAM (PPP) LOAN

On May 28, 2020, the ~~811,887 common shares~~Company obtained a Paycheck Protection Program (PPP) loan in the amount of $135,165. These business loans were established by the 2020 US Federal government Coronavirus Aid, Relief, and Economic Security Act (CARES Act) to ~~one (1) non-US person (as~~help certain businesses, self-employed workers, sole proprietors, certain nonprofit organizations, and tribal businesses continue paying their workers.

The CARES Act was established in order to enable small businesses to pay employees during the economic slowdown caused by COVID-19 by providing forgivable loans to qualifying businesses for up to 2.5 times their average monthly payroll costs. The amount borrowed under the CARES Act and used for payroll costs, rent, mortgage interest, and utility costs during the 24 week period after the date of loan disbursement is eligible to be forgiven provided that ~~term is defined in Regulation S~~(a) we use the PPP Funds during the eight week period after receipt thereof, and (b) the PPP Funds are only used to cover payroll costs (including benefits), rent, mortgage interest, and utility costs. While the full loan amount may be forgiven, the amount of loan forgiveness will be reduced if, among other reasons, we do not maintain staffing or payroll levels or less than 60% of the ~~Securities Act of 1933), in an offshore transaction relying~~loan proceeds are used for payroll costs. Principal and interest payments on ~~Regulation S~~any unforgiven portion of the ~~Securities~~PPP Funds will be deferred to the date the SBA remits the borrower’s loan forgiveness amount to the lender or, if the borrower does not apply for loan forgiveness, 10 months after the end of the borrower’s loan forgiveness period for six months and will accrue interest at a fixed annual rate of 1.0% and carry a two year maturity date. There is no prepayment penalty on the CARES Act Loan.

On June 17, 2021, the Small Business Administration (SBA) approved the Company’s PPP loan forgiveness application.

NOTE 7. NON-CONTROLLING INTEREST INVESTMENT IN BRAIN ARMOR, INC.

On March 30, 2021, a non-US investor subscribed to the acquisition of ~~1933,~~333,333 units of the Company’s Brain Armor Inc subsidiary. Each unit is comprised of one share of Brain Armor stock, $0.001 par value and a common stock purchase warrant evidencing the right to purchase one share of Common Stock at a per unit price of USD $0.30 for an aggregate purchase price of USD $100,000 which was received by the Company on March 30, 2021. The vesting and exercise prices of the warrants are as ~~amended.~~

~~Also~~follows:

	●	1/3 of shares shall be exercisable 6 months after the subscription date at an exercise price of $0.45 per share
	●	1/3 of shares shall be exercisable 12 months after the subscription date at an exercise price of $0.60 per share
	●	1/3 of shares shall be exercisable 18 months after the subscription date at an exercise price of $0.75 per share

Table of Contents

On May 5, 2021, a US investor subscribed to the acquisition of 3,333,333 units of the Company’s Brain Armor Inc subsidiary. Each unit is comprised of one share of Brain Armor stock, $0.001 par value and a common stock purchase warrant evidencing the right to purchase one share of Common Stock at a per unit price of USD $0.30 for an aggregate purchase price of USD $1,000,000 of which $100,000 was received by the Company on ~~September 12, 2017 we~~May 13, 2021 and $100,000 on May 27, 2021. This subscription agreement has since been terminated by mutual agreement of Brain Armor Inc. and the investor.

The vesting and exercise prices of the warrants are as follows:

	●	1/3 of shares shall be exercisable 6 months after the subscription date at an exercise price of $0.45 per share
	●	1/3 of shares shall be exercisable 12 months after the subscription date at an exercise price of $0.60 per share
	●	1/3 of shares shall be exercisable 18 months after the subscription date at an exercise price of $0.75 per share

NOTE 8. COMMITMENTS AND CONTINGENCIES

Everlast License Agreement

On December 23, 2013, the Company entered into a ~~Share Purchase~~Deed of Assignment Agreement ~~dated September 6, 2017 among our wholly owned subsidiary, Trident Brands~~with Everlast World’s Boxing Headquarters Corporation, International ~~Ltd. (“Trident International”),~~Brand Management Limited, Sports Nutrition Products Incorporated and Manchester Capital Incorporated wherein Everlast, International Brand, Sports Nutrition and Manchester Capital are parties to a ~~Bahamas~~trade mark license and Sports Nutrition, a New York corporation, ~~StreamPak Ltd. (“StreamPak”), an Anguilla corporation, and~~has assigned its interest in the ~~sole shareholder of StreamPak, pursuant~~trade mark license to ~~which, in consideration for~~ the ~~payment of $125,000 in cash and 500,000 of our common shares, Trident International purchased 100%~~Company. Pursuant to the terms of the ~~issued and outstanding common shares of StreamPak. As a result of the share purchase StreamPak became~~assignment agreement, Sports Nutrition Products Incorporated, a wholly owned subsidiary of Trident ~~International. We issued~~Brands Incorporated, assigned all of its rights, title, interest and benefit to the ~~500,000 common shares~~trade mark license to ~~one (1) non-US person (as that term is defined in Regulation S~~the Company effective December 23, 2013 and the Company assumed all of the ~~Securities Act~~obligations of ~~1933)~~Sports Nutrition Products Incorporated under the license agreement. The Company shall remain responsible to Everlast and International Brand for all acts and omissions of the subsidiary, Sports Nutrition Products Inc.

The Everlast License Agreement includes a clause stating that Manchester Capital Incorporated will guarantee that the Licensee shall perform all of its obligations and duties under the License Agreement. If the Licensee defaults in the payment when due of any amount it is obliged to pay to Licensor under the License Agreement, or arising from its termination, Manchester Capital is unconditionally responsible to pay that amount to Licensor in the manner prescribed in the License Agreement as if it were the Licensee.

Table of Contents

The Royalty Calculation, as per the terms of the agreement, are as follows: In 2013, 7% of Net Retail Sales and 7% of 60% of Direct Response Sales Revenue; in 2014, 8% of Net Retail Sales and 8% of 60% of Direct Response Sales Revenue; in 2015, 9% of Net Retail Sales and 9% of 60% of Direct Response Sales Revenue; in 2016 onwards, 10% of Net Retail Sales and 10% of 60% of Direct Response Sales Revenue. The Annual Minimum Guaranteed Royalty is $120,000 in 2014, $235,000 in 2015, $320,000 in 2016, $345,000 in 2017 and in 2018 onwards, if the Agreement remains in force, will be 75% of the previous Year’s Royalty Calculation or the previous Year’s Annual Minimum Guaranteed Royalty plus 10%, whichever is greater.

The agreement was terminated on December 31, 2017. On January 17, 2019, Everlast World’s Boxing Headquarters Corp. (“Everlast”) filed a counter civil lawsuit against the Company and other defendants. In that lawsuit, Everlast seeks payment from the defendants under a License Agreement dated June 4, 2013, for $425,555 in unpaid royalties allegedly due and owing under the License Agreement and interest on the allegedly unpaid royalties of $96,265, which interest allegedly continues to accrue. Everlast has also sought all costs, expenses, and legal fees incurred by Everlast in collecting monies that it claims are due under the License Agreement. On February 26, 2020, the court in the Everlast matter issued an Opinion and Order granting a motion to dismiss all of the Company’s claims against Everlast and granting a motion for judgment on the pleadings as to liability against the Company. The Court left open the question of damages to be awarded to Everlast. The Company had requested that the parties participate in settlement discussions before a magistrate judge or, in the alternative, that Everlast engage in limited discovery on these matters. No settlement was reached. On October 15, 2020, the Court in the Everlast case ordered, adjudged and decreed that Plaintiff Everlast have judgment and recover a total of $738,946 from the Company as follows:

1.	$425,000 representing royalty payments due to Everlast;
2.	Interest on royalty payments computed through October 15, 2020, in the sum of $242,920;
3.	Costs and attorneys’ fees in the sum of $71,026

The Company has fully accrued the $738,946 liability as of November 30, 2020.

On or about June 30, 2021, the Company, as Debtor, and Trident Sports Nutrition, Inc. and Brain Armor Inc., as garnishee defendants, were served with garnishment summons and complaint in Fond du Lac County, Wisconsin Circuit Court, (Case No. 2021FJ0003). The Plaintiff is Everlast, who is seeking to collect upon a judgment entered in the United States District Court for the Southern District of New York (Case No. 19-CV-503). According to Everlast, the judgment as of June 29, 2021 is in the amount of $745,814.61.

On July 16, 2021, the Company filed an Answer asserting that its assets are subject to the security interest of LDF (MCTECH) Investment Corp. and should not be subject to garnishment. Trident Sports Nutrition, Inc. and Brain Armor Inc. both filed garnishee answers denying that either corporation had control or possession of assets belonging to Trident Brands, Inc. or was otherwise indebted to the Company. The time period for Everlast to respond to these pleadings expires on August 5, 2021.

In addition, Everlast has commenced a proceeding in Waukesha County, Wisconsin Circuit Court (Case No. 21-TJ-90) and the Hon. Daniel P. Murray, Court Commissioner, has ordered the Company, Anthony M. Pallante and Peter Salvo to appear at his office for a supplemental examination on July 29, 2021 to answer under oath concerning the property and financial affairs of the Company. The Company and Messrs. Pallante and Salvo plan on defending against the Order issued by the Court Commissioner on jurisdictional and/or other grounds.

Banc of America Leasing and Capital

On December 1, 2020, Bank of America Leasing and Capital, LLC filed a legal action against the Company in the Superior Court for the State of California, County of San Mateo (Case NO. 20-CIV-05306), alleging breach of contract. The claim arises out of a software services contract between the Company and Oracle Corporation. Bank of America Leasing and Capital, LLC acquired Oracle’s rights under the agreement. The plaintiff claims the Company is liable for damages in the amount of $217,000 plus interests and costs. The Company did not file an answer to this complaint. On February 22, 2021, the plaintiff requested that the Court enter a default against the Company, which the court has done.

PIT Mycell

On June 3, 2019, the Company filed a lawsuit against PIT Mycell, LLC, William E. Peterson III, New Age Ventures, LLC, Volker Berl, and Mycell Technologies, LLC (“Mycell”) in the Superior Court in Bergen County, New Jersey, Civil Action No. BER-L-004198-19, in which the Company seeks to require the defendants to perform under and allow the enforcement of certain notes made by Mycell and acquired by the Company in September 2017. The notes are past their stated maturity date of December 31, 2016. The Company also alleges that the parties had entered into a written Settlement Agreement Letter of Intent dated March 14, 2019 (the “Settlement”), but that the defendants repudiated it shortly thereafter. The notes had been the subject of an earlier lawsuit in Virginia in state court in Fairfax County between the Company and PIT Mycell, LLC that the Settlement was intended to resolve. The Company seeks to enforce the notes and the Settlement in the New Jersey lawsuit and requests actual damages in an ~~offshore transaction relying~~amount to be proven at trial, attorneys’ fees and litigation costs, specific performance requiring certain defendants to enforce obligations under the notes against Mycell, specific performance requiring the defendants to execute a final Settlement Agreement consistent with the Settlement, an order permitting foreclosure on ~~Regulation S~~the collateral for the notes, and declaratory relief. On January 24, 2020, the New Jesey court denied Defendant’s Motions to dismiss the case. The parties have engaged in written discovery and exchanged productions of documents. Mycell filed for bankruptcy on November 25, 2020.

NOTE 9. SUBSEQUENT EVENTS

On June 17, 2021, the Small Business Administration (SBA) approved the Company’s PPP loan forgiveness application for the full amount of $135,165.

On June 30, 2021, the Board of Directors of the ~~Securities Act~~Company, unanimously consented to amend its Articles of ~~1933, as amended.~~

Incorporation to among other things authorize 29,432,320 shares of Preferred Stock, $0.001 par value.

On June 30, 2021, Everlast filed garnishment actions seeking to cause third parties who may be holding our money property (including Brain Armor, Inc.) to turn such property over to Everlast to satisfy the judgment it has against us. We have engaged counsel to represent us in connection with this matter.

Table of Contents

ITEM 2. ~~MANAGEMENT'S~~MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITIONS AND RESULTS OF OPERATIONS

Forward Looking Statements

The following Management’s Discussion and Analysis of Financial Condition and Results of Operations (“MD&A”) should be read in conjunction with the interim consolidated financial statements, and notes thereto, for the quarter ended ~~August~~May 31, ~~2017~~2021 contained under Item 1 of this Quarterly Report on Form 10-Q (“Form 10-Q”) and in conjunction with the annual consolidated financial statements, and notes thereto, contained in the Annual Report on Form 10-K for the fiscal year ended November 30, ~~2016~~2020 (“Form 10-K”). Unless otherwise indicated herein, the discussion and analysis contained in this MD&A includes information available ~~to October 16, 2017.~~

through July 20, 2021.

Certain statements contained in this MD&A may constitute forward-looking statements as defined under securities laws. Forward-looking statements may relate to our future outlook and anticipated events or results and may include statements regarding our future financial position, business strategy, budgets, litigation, projected costs, capital expenditures, financial results, taxes, plans and objectives. In some cases, forward-looking statements can be identified by terms such as “anticipate”, “estimate”, “intend”, “project”, “potential”, “continue”, “believe”, “expect”, “could”, “would”, “should”, “might”, “plan”, “will”, “may”, “predict”, the negatives of such terms, and other similar expressions concerning matters that are not historical facts. To the extent any forward-looking statements contain future-oriented financial information or financial outlooks, such information is being provided to enable a reader to assess our financial condition, material changes in our financial condition, our results of operations, and our liquidity and capital resources. Readers are cautioned that this information may not be appropriate for any other purpose, including investment decisions.

Forward-looking statements contained in this MD&A are based on certain factors and assumptions regarding expected growth, results of operations, performance, and business prospects and opportunities. While we consider these assumptions to be reasonable, based on information currently available, they may prove to be incorrect. Forward-looking statements are also subject to certain factors, including risks and uncertainties that could cause actual results to differ materially from what we currently expect. These factors are more fully described in the “Risk Factors” section at Item 1A of the Form 10-K.

Forward-looking statements contained in this commentary are based on our current estimates, expectations and projections, which we believe are reasonable as of the date of this report. You should not place undue importance on forward-looking statements and should not rely upon this information as of any other date. Other than as required under securities laws, we do not undertake to update any forward-looking information at any particular time.

All dollar amounts in this MD&A are expressed in thousands of U.S. dollars ~~except per share amounts,~~ unless otherwise noted.

~~Business Developments~~

~~Effective December 12, 2016 we made the following changes to our officers and directors:~~

·	~~Donald MacPhee resigned as a Director of the Board of Directors, Chair of the Audit Committee and as President and Chief Executive Officer, and was appointed Director of Operations;~~

·	~~Anthony Pallante was appointed as Director and Chairman of our Board of Directors, and as Chief Executive Officer;~~

·	~~Mark Holcombe resigned as Chairman of the Board of Directors and was appointed as President, Director and Chair of the Compensation Committee.~~

·	~~Scott Chapman, our Director and Chair of the Corporate Governance Committee, was also appointed as Chair of the Audit Committee.~~

·	~~Michael Browne resigned as Corporate Secretary of Trident Brands Incorporated and will continue to serve as Brand Director, Chief Financial Officer, and Treasurer; and~~

·	~~Peter Salvo, Controller of the Company was also appointed as Corporate Secretary.~~

On February 15, 2017, we entered into a Letter of Intent (the “LOI”) with The Activation Group, Inc., an integrated marketing and advertising agency incorporated in Ontario, Canada. Pursuant to the LOI, we will seek to enter into a definitive agreement to purchase all the issued and outstanding common shares of The Activation Group in consideration for a purchase price consisting of $200,000 cash, and $800,000 payable in common shares of Trident. The cash consideration is inclusive of a $50,000 deposit paid to The Activation Group upon execution of the LOI, and $150,000 payable upon closing a definitive agreement. Stock payments shall be payable in four $200,000 installments, subject to the achievement of earnings targets. The transaction contemplated by the LOI will be subject to the satisfactory completion of due diligence, and to the negotiation and completion of a definitive agreement among the parties and the shareholders of The Activation Group.

Also, on February 15, 2017, our board of directors appointed Mark Cluett as the Chief Operating Officer at Trident Brands Incorporated, with responsibility for business strategy execution and commercialization.

On September 12, 2017 the Company entered into a note purchase agreement with Fengate Trident LP pursuant to which, in consideration for the issuance of 811,887 of our common shares to Fengate, we purchased outstanding secured convertible promissory notes of Mycell Technologies LLC having an aggregate balance due and payable of $511,141.17 in principal and $94,526.11 in interest accrued as at September 12, 2017. The purchased notes, which were originally issued to LPF (MCTECH) Investment Corp. on January 22, 2016, February 5, 2016, and May 19, 2016, bear simple interest on unpaid principal at the rate of ten percent per annum. The outstanding principal and accrued interest is convertible at the option of the note holder into securities of Mycell. We issued the 811,887 common shares to one (1) non-US person (as that term is defined in Regulation S of the Securities Act of 1933), in an offshore transaction relying on Regulation S of the Securities Act of 1933, as amended.

Also on September 12, 2017 we entered into a Share Purchase Agreement dated September 6, 2017 among our wholly owned subsidiary, Trident Brands International Ltd. (“Trident International”), a Bahamas corporation, StreamPak Ltd. (“StreamPak”), an Anguilla corporation, and the sole shareholder of StreamPak, pursuant to which, in consideration for the payment of $125,000 in cash and 500,000 of our common shares, Trident International purchased 100% of the issued and outstanding common shares of StreamPak. As a result of the share purchase StreamPak became a wholly owned subsidiary of Trident International. We issued the 500,000 common shares to one (1) non-US person (as that term is defined in Regulation S of the Securities Act of 1933), in an offshore transaction relying on Regulation S of the Securities Act of 1933, as amended.

Results of Operations

The following summary of our results of operations should be read in conjunction with our unaudited consolidated financial statements for the three ~~month~~ and ~~nine~~six month periods ended ~~August~~May 31, ~~2017~~2021 and ~~August~~May 31, ~~2016.~~

2020.

Table of Contents

Our operating results for three month periods ended ~~August~~May 31, ~~2017~~2021 and ~~August~~May 31, ~~2016~~2020 are summarized as follows:

Three Months
Ended

Three Months
Ended

August 31, 2017 August 31, 2016

Revenues $ 3,277,655 $ 17,028
Gross Profit $ 160,505 $ 7,640
Operating Expenses $ 908,378 $ 502,659
Other Expenses $ 489,593 $ 79,269
Net Loss $ 1,237,466 $ 574,288

	Three Months Ended			Three Months Ended
	May 31,			May 31,
	2021			2020

Revenues	$	46,243		$	244,102
Gross Profit	$	21,663		$	76,862
Operating Expenses	$	537,978		$	1,119,556
Other Expenses	$	200,008		$	(9,019,748	)
Net Loss	$	(716,323	)	$	(10,062,442	)

Add back:
Interest Expense	$	200,008		$	1,001,119
Depreciation	$	-0-		$	2,095
Amortization	$	-0-		$	-0-

EBITDA	$	(516,315	)	$	(9,059,228	)

Add back:
Derivative Loss	$	-0-		$	8,028,629

Adjusted EBITDA	$	(516,315	)	$	(1,030,599	)

Table of Contents

Revenues and Gross Profits

~~Revenue increased substantially~~

Sales in the first quarter of 2021 decreased to ~~$3,277,655~~$46,243 versus ~~$17,028~~$244,102 in the prior year. This growth is attributed to a significant contract manufacturing supply agreement with a major retailer, coupled with increased direct sales of Brain Armor® products to professional sports teams and collegiate programs. Gross Profit increased to $160,505 or 4.9% of revenues versus $7,640 or 44.9% of revenues inperiod. The decrease was the ~~prior year as a~~ result of the ~~increase in sales. Management continues~~inability to ~~direct operational support and focus toward markets, distribution channels and customers that represent sustainable commercial value. As such, we~~fulfill various purchase orders due to out of stock (OOS) of certain SKU’s. We expect ~~further revenue and~~this lack of supply to resolve over the next three months. Gross profit ~~growth in the remainder~~decreased to $21,663 (46.8% of 2017 and 2018. This outlook is supported by expanded retail customer supply agreements and new item listings coupled with further product innovation scheduled for introduction in Q4 2017 and Q1 2018.

revenues) versus $76,862 (31.5% of revenues).

Operating Expenses

Our operating expenses for the three month ~~periods~~period ended ~~August~~May 31, ~~2017~~2021 and ~~August~~May 31, ~~2016 are~~2020 is summarized below:

Three Months
Ended

Three Months
Ended

August 31, 2017 August 31, 2016

Professional Fees $ 41,618 $ 11,716
General & Administrative Expenses $ 461,330 $ 235,826
Marketing, Selling & Warehousing Expenses
$
274,254
$
142,359
Management Salary $ 21,000 $ 12,000
Director's Fees $ 21,000 $ 18,000
Rent $ 2,926 $ 2,171
Royalty $ 86,250 $ 80,587

	Three Months Ended May 31,		Three Months Ended May 31,
	2021		2020
Professional Fees	$	80,478	$	120,235
General & Administrative Expenses	$	374,804	$	622,589
Marketing, Selling & Warehousing Expenses	$	34,451	$	326,557
Management Salary	$	47,500	$	35,125
Rent	$	745	$	15,050

Operating expenses for the three month period ended ~~August~~May 31, ~~2017~~2021 were ~~$908,378~~$537,978 as compared to ~~$502,659~~$1,119,556 for the comparative period in ~~2016, an increase~~2020, a decrease of ~~81%~~51.9%. The ~~increase~~decrease in our operating expenses was primarily due to ~~increased~~a decrease in general & administrative expenses as a result of cost reductions and ~~administrative costs~~decreased marketing and selling expenses related to the decrease in sales. Legal expenses also decreased by $45,571. Subject to raising additional capital, we expect our operating expenses to increase as we ~~build out~~ramp up our ~~organization and roll-out our product offering. These costs are expected to continue to increase throughout 2017 as we continue to develop and commercialize our product offerings.~~

selling activities

Other Expenses

Other expenses for the three month period ended ~~August~~May 31, 2021 were $200,008 as compared to $9,019,748 for the comparative period in 2020, a decrease of 97.8%. The decrease in other expenses was primarily due to a decrease in non-cash derivative loss of $8,028,629 and a decrease in interest expense of $801,111 related to lower debt levels of $358,135, elimination of non-cash interest expense related to the impact of amortization of debt discount from convertible notes entered into in 2016, 2017 ~~increased~~and 2018 of $168,410, and non-cash derivative loss of $274,566 on the revaluation of the embedded conversion option of all the convertible notes. This was partially offset by a $10,000 gain on debt forgiveness in the prior period. We expect interest expense to ~~$489,593 versus $79,269~~remain constant.

Non-GAAP Financial Measure

The following non-GAAP financial measures are presented in this quarterly report on Form 10-Q to supplement the financial information we present on a GAAP basis. We monitor and present EBITDA and Adjusted EBITDA because they are key measures used by our management to understand and evaluate our performance.

EBITDA

We define EBITDA as net income (loss), adjusted to exclude: Interest income and expense, depreciation and amortization expense including impairment loss. Reported net loss for the three month period May 31, 2021 was $(716,323) compared to $(10,062,442) in the comparative period in ~~2016. The increase~~2020. After deducting interest, depreciation and amortization, EBITDA for the three month period ended May 31, 2021 was ~~due~~($516,315) compared to ~~an increase~~($9,059,226) in ~~interest~~2020.

Adjusted EBITDA

We define Adjusted EBITDA as EBITDA, adjusted to exclude: stock options expense ~~due~~and derivative loss. Reported EBITDA for the three month period May 31, 2021 was ($516,315) compared to ~~higher debt levels~~($9,059,228) in the comparative period in 2020. After deducting non-cash stock options expense and derivative loss, Adjusted EBITDA for the ~~impact of certain other items including the beneficial conversion feature related~~three month period ended May 31, 2021 was ($516,315) compared to ~~the convertible note entered into~~($1,030,599) in ~~2017.~~

~~Nine~~2020.

Table of Contents

Six Month Periods Ended ~~August~~May 31, ~~2017~~2021 and ~~August~~May 31, ~~2016~~

2020

Our operating results for ~~the nine~~six month periods ended ~~August~~May 31, ~~2017~~2021 and ~~August~~May 31, ~~2016~~2020 are summarized as follows:

Nine Months
Ended

Nine Months
Ended

August 31, 2017 August 31, 2016

Revenues $ 3,305,644 $ 241,053
Gross Profit $ 173,378 $ 105,689
Operating Expenses $ 2,375,051 $ 1,755,774
Other Expenses $ 1,048,283 $ 351,353
Net Loss $ 3,249,956 $ 2,001,438

	Six Months Ended May 31, 2021			Six Months Ended May 31, 2020

Revenues	$	190,291		$	405,987
Gross Profit	$	86,923		$	153,818
Operating Expenses	$	942,262		$	2,433,290
Other Expenses	$	400,341		$	12,039,149
Net Loss	$	(1,255,680	)	$	(14,318,621	)

Add back:
Interest Expense	$	400,341		$	2,447,807
Depreciation	$	-0-		$	4,191
Amortization	$	-0-		$	-0-

EBITDA	$	(855,339	)	$	(11,866,623	)

Add back:
Stock Options Expense	$	-0-		$	-0-
Derivative Loss	$	-0-		$	9,601,342

Adjusted EBITDA	$	(855,339	)	$	(2,265,281	)

Revenues and Gross ~~Profit~~

~~Revenue increased substantially for~~Profits

Sales in the ~~nine month period ended August 31, 2017~~first half of fiscal 2021 decreased to ~~$3,305,644~~$190,291 versus ~~$241,053~~$405,987 in the prior ~~year. This growth is attributed~~period. The decrease was the result of the inability to ~~a significant contract manufacturing~~fulfill various purchase orders due to out of stock (OOS) of certain SKU’s. We expect this lack of supply ~~agreement with a major retailer, coupled with increased direct sales~~to resolve over the next three months. Gross profit decreased to $86,923 (45.7% of ~~Brain Armor® products to professional sports teams and collegiate programs. This translated into a corresponding increase in Gross Profit to $173,378 or 5.2%~~revenues) versus $153,818 (37.9% of revenues versus $105,689 or 43.8% of revenues in the prior year. Management continues to direct operational support and focus toward markets, distribution channels and customers that represent sustainable commercial value. As such, we expect further revenue and profit growth in the remainder of 2017 and 2018. This outlook is supported by expanded retail customer supply agreements and new item listings coupled with further product innovation scheduled for introduction in Q4 2017 and Q1 2018.

revenues).

Table of Contents

Operating Expenses

Our operating expenses for the ~~nine~~six month ~~periods~~period ended ~~August~~May 31, ~~2017~~2021 and ~~August~~May 31, ~~2016 are~~2020 is summarized below:

Nine Months
Ended

Nine Months
Ended

August 31, 2017 August 31, 2016

Professional Fees $ 133,796 $ 111,469
General & Administrative Expenses $ 1,281,536 $ 767,121
Marketing, Selling & Warehousing Expenses
$
569,531
$
550,954
Management Salary $ 63,000 $ 32,500
Director's Fees $ 63,000 $ 54,000
Rent $ 7,521 $ 6,016
Royalty $ 256,667 $ 233,714

	Six Months Ended May 31, 2021		Six Months Ended May 31, 2020
Professional Fees	$	94,127	$	279,843
General & Administrative Expenses	$	699,750	$	1,476,618
Marketing, Selling & Warehousing Expenses	$	61,481	$	571,384
Management Salary	$	85,000	$	73,375
Director’s Fees	$	-0-	$	-0-
Rent	$	1,904	$	32,070

Operating expenses for the ~~nine~~six month period ended ~~August~~May 31, ~~2017~~2021 were ~~$2,375,051~~$942,262 as compared to ~~$1,755,774~~$2,433,290 for the comparative period in ~~2016, an increase~~2020, a decrease of ~~35.3%~~61.3%. The ~~increase~~decrease in our operating expenses iswas primarily due to ~~increased~~a decrease in legal expenses of $184,438 and a decrease in general administration and ~~administrative costs~~marketing and selling expenses related to the decrease in sales. Subject to raising additional capital, we expect our operating expenses to increase as we ~~build and roll-out~~ramp up our ~~product offerings. These costs are expected to continue to increase throughout 2017 as we continue to develop and commercialize our product offerings.~~

selling activities.

Other Expenses

Other expenses for the ~~nine~~six month period ended ~~August~~May 31, ~~2017 increased~~2021 were $400,341, compared to ~~$1,048,283 versus $351,353~~$12,039,149 in the comparative period in ~~2016.~~2020, a decrease of 96.7%. The ~~increase~~decrease in other expenses was primarily due to ~~an increase~~a decrease in non-cash derivative loss of $9,601,342 (on the revaluation of the embedded conversion option of all the convertible notes), a $2,047,466 decrease in interest expense ~~due~~(related to ~~higher~~lower debt ~~levels~~levels), and a $1,339,440 decrease in non-cash interest expense (related to the impact of ~~certain other items including~~ the ~~beneficial conversion feature related to the~~amortization of debt discount from convertible ~~note~~notes entered into in ~~2017.~~

2016 and 2018). We expect interest expenses to remain constant.

Non-GAAP Financial Measure

EBITDA

We define EBITDA as net income (loss), adjusted to exclude: Interest income and expense, depreciation and amortization expense including impairment loss. Reported net loss for the six month period May 31, 2021 was $1,255,680 compared to $14,318,621 in the comparative period in 2020. After deducting interest, depreciation and amortization, EBITDA for the six month period ended May 31, 2021 was ($855,338) compared to ($11,866,623) in 2020.

Adjusted EBITDA

We define Adjusted EBITDA as EBITDA, adjusted to exclude stock options expense and derivative loss. Reported EBITDA for the six month period May 31, 2021 was ($855,338) compared to ($11,866,623) in the comparative period in 2020. After deducting non-cash stock options expense and derivative loss, Adjusted EBITDA for the six month period ended May 31, 2021 was ($855,338) compared to ($2,265,281) in 2020.

Table of Contents

Balance Sheet Data

The following table provides selected balance ~~sheet~~sheets data as at ~~August~~May 31, ~~2017 and August 31, 2016.~~

Balance Sheet Data: August 31, 2017 August 31, 2016

Cash $ 4,380,378 $ 4,484
Total assets $ 7,755,321 $ 3,006,386
Total liabilities $ 11,053,311 $ 4,736,704
Stockholders' (deficit) $ (3,297,990 ) $ (1,730,318 )

Total assets and total liabilities increased in the nine month period ended August 31, 2017 versus the corresponding period last year as a result of the receipt of additional financing in September 20162021 and May ~~2017.~~

31, 2020.

Balance Sheet Data:	May 31, 2021			May 31, 2020

Cash and cash equivalents	$	131,361		$	277,334
Total assets	$	1,779,360		$	2,909,624
Total liabilities	$	31,153,522		$	45,745,898
Stockholders’ (deficit)	$	(29,374,162	)	$	(42,836,274	)

Strategic Orientation

Our objective is to provide our shareholders with solid returns through strategic investments across multiple consumer product and ~~food~~ ingredient platforms. The platforms we are focusing on include:

●

Life science technologies and related products that have applications to a range of consumer products;

●

Nutritional supplements and related consumer goods providing defined benefits to the consumer; and

●

Functional foods and beverages ingredients with defined health and wellness benefits.

We are building our business through strategic investments in high growth early stage consumer brands and functional ~~ingredients~~ingredient platforms within segment/sectors which we believe offer ~~long term growth~~sustainable commercial potential. We are focused on three core strategies underpinning our objectives:

●

To execute ~~our~~a multi-tier brand, supply-chain and innovation strategy to drive revenue;

●

To aggressively manage ~~our~~an asset light business model to drive a low cost platform; and

·	~~To drive disciplines leading to increased investor awareness and ability to finance and govern growing operations.~~

While we have yet to ~~realize break even cash flows or~~achieve profitability, we believe we are making significant progress against our ~~goals~~commercial objectives. We expect revenue and ~~objectives, and expect revenues and margins~~margin to increase as we ~~begin commercializing the products~~continue to strengthen distribution partnerships while capitalizing on product innovation, supply-chain optimization and brand equity within our current portfolio. ~~All three of our product platforms show solid potential in the markets where they compete and both our~~ ~~Everlast® and~~ ~~Brain Armor~~® product lines are now in the market and generating revenues. Our strategy was to first establish listings for these products with non-bricks and mortar accounts, and this has been successful. Brain ~~Armor~~® has now been listed at a large retail account as well, and we expect listings for Everlast® to follow. The development of Oceans Omega as an ingredient for food and beverage products is ongoing, and given the longer sales cycle for ingredients, we expect to realize revenues later in fiscal 2017 both through external customer product development and also internally via potential line extensions for both the E~~verlast® and~~ ~~Brain Armor® product lines.~~

Liquidity and Capital Resources

~~Our cash balance at August 31, 2017 was $4,380,378. Management believes the current funds available to~~

The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern, which contemplates realization of assets and the satisfaction of liabilities in the normal course of business within one year after the date the consolidated financial statements are issued. In accordance with Financial Accounting Standards Board, or the FASB, Accounting Standards Update No. 2014-15, Presentation of Financial Statements - Going Concern (Subtopic 205-40), our management evaluates whether there are conditions or events, considered in aggregate, that raise substantial doubt about our ability to continue as a going concern within one year after the date that the financial statements are issued.

As of May 31, 2021, the Company had $131,361 in cash and a working capital deficit of $7,338,997. The Company has historically generated losses and negative operating cash flows. The Company has an accumulated deficit of $40,703,867 as of May 31, 2021. These factors raise substantial doubt about the ability of the Company to continue as a going concern. Unless management is able to obtain additional financing, the Company may not be ~~sufficient~~able to ~~fund our operations for~~meet its funding requirements during the next ~~twelve~~12 months.

~~On January 29, 2015, we entered into a securities purchase agreement with a non-US institutional investor whereby we agreed to sell~~ The financial statements do not include any adjustments that might result from the outcome of this uncertainty.

Working Capital Deficiency and Need for Additional Capital

Between March 22 and May 27, 2021, Brain Armor, Inc, the Company’s majority owned subsidiary, sold an aggregate ~~principal amount~~ of ~~$2,300,000~~1,000,000 Units, each comprised of ~~senior secured convertible debentures, convertible into shares~~one share of ~~the company’s~~ common ~~stock. We received $1,800,000~~stock and a warrant to purchase one share of the funds from the transaction on February 5, 2015 and the balance of $500,000 on May 14, 2015. On September 26, 2016, we entered into a Convertible Promissory Note Amendment Agreement with this investor whereby we agreed to extend the maturity date and amend the interest payable on the senior secured convertible debentures, whereby we extended the term of the notes through September 30, 2019 and interest rate was increased from 6% per annum to 8% per annum. The convertible debentures are convertible into shares of the Company’s common stock, at ~~an initial conversion~~a per Unit price of ~~$0.71 per share~~$.30, for ~~an aggregate of up to 3,239,437 shares.~~

~~On September 26, 2016, we entered into a Securities Purchase Agreement with a non-US institutional investor pursuant to which, in consideration for~~gross proceeds of ~~$4,100,000,~~$300,000.

We currently have a severe working capital deficiency. As of May 31, 2021, we ~~issued~~had a ~~secured convertible promissory note~~working capital deficit of approximately $7.3 million, compared to a deficit of approximately $6.4 million as of November 30, 2020. The approximate $0.9 million decrease in working capital deficit was due primarily to (all amounts approximate) an increase in accrued liabilities of $0.8 million.

As disclosed under Item 3. Legal Proceedings, a judgment was entered against us in the Everlast matter in the amount of ~~$4,100,000. Pursuant~~approximately $740,000. Everlast has since filed a garnishment action seeking to cause third parties who may be holding our money property (including Brain Armor, Inc.) to turn such property over to Everlast to satisfy the ~~Securities Purchase Agreement,~~judgment it has against us. In addition, the ~~investor has agreed, from time to time after January 1, 2017, to make additional investments at our request of up to $5,900,000 ($10,000,000~~plaintiff in the ~~aggregate)~~Oracle matter has requested a default judgment against us. Accordingly, the Company is currently obligated to pay Everlast approximately $740,000 and could be liable to pay Oracle at least $217,000 if the court enters a default judgment, in ~~one or more tranches~~which case, the Company would be liable for in excess of ~~not less than one tranche during any 60 day period. The funding of any tranche under~~$1 million in judgments, in the ~~agreement (other than~~aggregate. If the ~~first $4,100,000 which has been funded)~~Company is ~~subject~~compelled to pay these liabilities, there would be a material adverse effect on the ~~mutual agreement~~financial condition of the Company. On June 30, 2021, Everlast filed garnishment actions seeking to cause third parties aswho may be holding our money property (including Brain Armor, Inc.) to turn such property over to Everlast to satisfy the ~~use~~judgment it has against us. We have engaged counsel to represent us in connection with this matter.

Table of Contents

As of ~~funds. The parties~~July 20, 2021, we had only minimal cash on hand, and consequently, we are unable to fully implement our current business plan. Accordingly, we have ~~agreed~~an immediate need for additional capital to ~~negotiate in good faith~~fund our operating activities. COVID-19 has thus far adversely affected our revenues and our ability to ~~pre-approve use~~raise additional capital, so there is no assurance we will be able to grow our business or raise sufficient additional capital on acceptable terms or at all.

In order to remedy this liquidity deficiency, we are actively seeking to raise additional funds through the sale of equity and/or debt securities, and ultimately, we will need to generate substantial positive operating cash flows. Our internal sources of funds ~~within 120 days following September 26, 2016. On May 9, 2017,~~will consist of cash flows from operations, but not until we begin to realize additional revenues from the ~~Company received~~sale of our products and services. As previously stated, our operations are generating negative cash flows, and thus adversely affecting our liquidity. If we are unable to raise additional funds in the second tranche of funding with proceeds of $4,400,000 for a total investment by the investor of $8,500,000. Under the terms of the securities purchase agreement, the Company has an additional $1,500,000 of available funding. We intend to use the proceeds of the secured convertible note for general working capital purposes including, without limitation, settlement of accounts payable and repayment of mature loans. In consideration of each advance made by the investor pursuant to the Securities Purchase Agreement,near term, we will ~~issue~~not be able to implement our business plan, in which case there would be a material adverse effect on our results of operations and financial condition.

In the investor a convertible promissory note of equal value, maturing three years after issuance, and bearing interest at the rate of 8% per annum. Each note will be secured in first priority against the present and after acquired assets of the Company, and will be convertible in wholeevent we do not generate sufficient funds from revenues or in part at the option of the holder into common shares of the Company at a conversion price per share of $0.60, equal to a 25% discount to the 10 day average closing price of the Company’s common stock for the period immediately precedingfinancing through the issuance of ~~the applicable note. Due~~common stock or from debt financing, we will be unable to ~~the notes being convertible~~fully implement our business plan and pay our obligations as they become due, any of which circumstances would have a material adverse effect on our business prospects, financial condition, and results of operations. The accompanying financial statements do not include any adjustments that might be required should we be unable to recover the ~~Company common shares, a beneficial conversion feature analysis was performed. The intrinsic~~ value of ~~the conversion feature was $1,366,667~~our assets or satisfy our liabilities.

Based on our limited availability of funds we expect to spend minimal amounts on product development, sales and ~~$1,466,667 respectively~~marketing and capital expenditures. We expect to fund any future product development expenditures through a combination of cash flows from operations and proceeds from equity and/or debt financing. If we are unable to generate positive cash flows from operations, and/or raise additional funds (either through debt or equity), we will be unable to fund our product development expenditures, in which ~~was recognized as debt discount. As~~case, there could be a material adverse effect on our business and results of ~~August 31, 2017, $612,869 of debt discount was amortized of which $532,038 was amortized during the current nine month period and $80,831 in the prior year. The unamortized discount is $2,220,465.~~

operations.

Off-Balance Sheet Arrangements

We do not have any off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that is material to investors.

Contractual Obligations

Except for the transactions noted in Business Developments, there have been no material changes outside the normal course of business in our contractual obligations since January 3, 2015.

Critical Accounting Estimates

The preparation of financial statements in conformity with U.S. GAAP requires management to make certain estimates and assumptions that affect the reported amounts of assets and liabilities, related revenues and expenses, and disclosure of gain and loss contingencies at the date of the financial statements. The estimates and assumptions made require us to exercise our judgment and are based on historical experience and various other factors that we believe to be reasonable under the circumstances. We continually evaluate the information that forms the basis of our estimates and assumptions as our business and the business environment generally changes. The use of estimates is pervasive throughout our financial statements. There have been no material changes to the critical accounting estimates disclosed under the heading “Critical Accounting Estimates” in Item 7, “Management’s Discussion and Analysis of Financial Condition and Results of Operations”, of the Form 10-K.

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

As a smaller reporting company we are not required to provide this information.

ITEM 4. CONTROLS AND PROCEDURES

Evaluation of Disclosure Controls and Procedures

Under the supervision and with the participation of our management, including our principal executive officer and the principal financial officer, we have conducted an evaluation of the effectiveness of the design and operation of our disclosure controls and procedures, as defined in Rules 13a-15(e) and 15d-15(e) under the Securities and Exchange Act of 1934, as of the end of the period covered by this report. Based on this evaluation, our principal executive officer and principal financial officer concluded as of the evaluation date that our disclosure controls and procedures were not effective such that the material information required to be included in our Securities and Exchange Commission reports is accumulated and communicated to our management, including our principal executive and financial officer, recorded, processed, summarized and reported within the time periods specified in SEC rules and forms relating to our company, particularly during the period when this report was being prepared.

Changes in Internal Controls Over Financial Reporting

Our management, with the participation of our principal executive officer and principal financial officer have concluded that there have been no changes in our internal control over financial reporting that occurred during the ~~last~~ fiscal quarter ended ~~August~~May 31, ~~2017~~2021 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

Table of Contents

PART II. OTHER INFORMATION

Item 1. Legal Proceedings

On January 11, 2019, the Company filed a lawsuit against Everlast World’s Boxing Headquarters Corp. (“Everlast”). This action involves Everlast’s attempts to prevent the Company from exercising its right to terminate a License Agreement between the parties pursuant to which Trident had the right to market certain Everlast-branded products.

On January 17, 2019, Everlast World’s Boxing Headquarters Corp. (“Everlast”) filed a counter civil lawsuit against the Company and other defendants. In that lawsuit, Everlast seeks payment from the defendants under a License Agreement dated June 4, 2013, for $425,555 in unpaid royalties allegedly due and owing under the License Agreement and interest on the allegedly unpaid royalties of $96,265, which interest allegedly continues to accrue. Everlast has also sought all costs, expenses, and legal fees incurred by Everlast in collecting monies that it claims are due under the License Agreement. On February 26, 2020, the court in the Everlast matter issued an Opinion and Order granting a motion to dismiss all of the Company’s claims against Everlast and granting a motion for judgment on the pleadings as to liability against the Company. The Court left open the question of damages to be awarded to Everlast. The Company has requested that the parties participate in settlement discussions before a magistrate judge or, in the alternative, that Everlast engage in limited discovery on these matters. No settlement was reached. On October 15, 2020, the Court in the Everlast case ordered, adjudged and decreed that Plaintiff Everlast have judgment and recover a total of $738,946 from the Company as follows:

1.	$425,000 representing royalty payments due to Everlast;
2.	Interest on royalty payments computed through October 15, 2020, in the sum of $242,920;
3.	Costs and attorneys’ fees in the sum of $71,026

The Company has fully accrued the $738,946 liability as of November 30, 2020.

The Clerk of Court was directed to close the case. The Company did not appeal the judgement.

On June 3, 2019, the Company filed a lawsuit against PIT Mycell, LLC, William E. Peterson III, New Age Ventures, LLC, Volker Berl, and Mycell Technologies, LLC (“Mycell”) in the Superior Court in Bergen County, New Jersey, Civil Action No. BER-L-004198-19, in which the Company seeks to require the defendants to perform under and allow the enforcement of certain notes made by Mycell and acquired by the Company in September 2017. The notes are past their stated maturity date of December 31, 2016. The Company also alleges that the parties had entered into a written Settlement Agreement Letter of Intent dated March 14, 2019 (the “Settlement”), but that the defendants repudiated it shortly thereafter. The notes had been the subject of an earlier lawsuit in Virginia in state court in Fairfax County between the Company and PIT Mycell, LLC that the Settlement was intended to resolve. The Company seeks to enforce the notes and the Settlement in the New Jersey lawsuit and requests actual damages in an amount to be proven at trial, attorneys’ fees and litigation costs, specific performance requiring certain defendants to enforce obligations under the notes against Mycell, specific performance requiring the defendants to execute a final Settlement Agreement consistent with the Settlement, an order permitting foreclosure on the collateral for the notes, and declaratory relief. On January 24, 2020, the New Jersey court denied Defendant’s Motions to dismiss the case. The parties have engaged in written discovery and exchanged productions of documents. Mycell filed for bankruptcy on November 25, 2020.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

Between March 22 and May 27, 2021, Brain Armor, Inc, the Company’s majority owned subsidiary, sold an aggregate of 1,000,000 Units, each comprised of one share of common stock and a warrant to purchase one share of common stock, at a per Unit price of $0.30, for gross proceeds of $300,000.

We believe that the foregoing transactions were exempt from the registration requirements under the Securities Act of 1933, as amended (“the Act”), based on the following facts: there was no general solicitation, there was a limited number of purchasers, each of whom the Registrant believes was an “accredited investor” (within the meaning of Regulation D under the Securities Act of 1933, as amended) and was sophisticated about business and financial matters, and all shares issued were subject to restriction on transfer, so as to take reasonable steps to assure that the purchaser was not an underwriter within the meaning of Section 2(11) under the Act.

Table of Contents

ITEM 6. EXHIBITS

The following exhibits are included with this quarterly filing:

Exhibit No.		Description

3.1		Articles of Incorporation*Incorporation, as amended
~~3.2~~		Bylaws*
~~31.1~~ 3.2		Bylaws*

4.1		Subscription Agreement between Grant Roberts, Inc. and Brain Armor, Inc. dated May 5, 2021 and since terminated (after $200,000 invested)

31.1		Sec. 302 Certification of Chief Executive Officer
~~31.2~~
31.2		Sec. 302 Certification of Chief Financial Officer
~~32.1~~
32.1		Sec. 906 Certification of Chief Executive Officer
~~32.2~~
32.2		Sec. 906 Certification of Chief Financial Officer
~~101~~
101		Interactive data files pursuant to Rule 405 of Regulation S-T.

__________

*Document is incorporated by reference and can be found in its entirety in our Registration Statement on Form SB-2, SEC File Number 333-148710, at the Securities and Exchange Commission website at www.sec.gov.

Document is incorporated by reference and can be found in its entirety in our Registration Statement on Form SB-2, SEC File Number 333-148710, at the Securities and Exchange Commission website at www.sec.gov.25

Table of Contents

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

~~October 16, 2017~~	Trident Brands Incorporated

Date: July 20, 2021
By:	/s/ Anthony Pallante
	~~By:~~	Anthony Pallante
		(Chief Executive Officer & Chair of the Board)

	By:	/s/ Peter Salvo
		Peter Salvo
		(Principal Financial Officer)



	~~/s/ Mike Browne~~
	~~By: Mike Browne~~
	~~(Chief Financial Officer)~~


	~~/s/ Mark Holcombe~~
	~~By: Mark Holcombe~~
	~~(President & Director)~~


	~~/s/ Scott Chapman~~
	~~By: Scott Chapman~~
	~~(Director)~~26

Large accelerated filer ~~[ ]~~	☐	Accelerated filer ~~[ ]~~	☐
Non-accelerated filer ~~[ ]~~	☒	Smaller reporting company ~~[X]~~	☒
Emerging Growth Company	☒

	As of			As of
	August 31, 2017			November 30, 2016
ASSETS

Current Assets
Cash	$	4,130,378		$	1,527,624
Restricted Cash		250,000			-
Accounts Receivable		661,799			53,053
Inventory		274,367			231,221
Prepaid		210,748			67,332
Total Current Assets		5,527,292			1,879,230

Fixed Assets-Furniture & Fixtures, net		28,029			-
Intangible Assets - Licenses, net		2,200,000			2,425,000

TOTAL ASSETS	$	7,755,321		$	4,304,230

LIABILITIES & STOCKHOLDERS' DEFICIT

Current Liabilities
Accounts Payable	$	1,322,818		$	106,612
Accrued Liability		1,150,958			431,178
Loan Payable - Third Party, net of discount $0 and $8,812, respectively		-			191,188
Total Current Liabilities		2,473,776			728,978

Convertible Debt, net of discount $2,220,465 and $1,285,836, respectively		8,579,535			5,114,164

Total Liabilities		11,053,311			5,843,142

Stockholders' Deficit
Common stock, $0.001 par value, 300,000,000 shares authorized;
31,000,000 shares issued and outstanding as of August 31, 2017 and November 30, 2016		31,000			31,000
Additional paid-in capital		6,922,854			5,431,976
Non-Controlling Interest in Subsidiary		(95,183	)		(65,786	)
Accumulated Deficit		(10,156,661	)		(6,936,102	)
Total Stockholders' Deficit		(3,297,990	)		(1,538,912	)

TOTAL LIABILITIES & STOCKHOLDERS' DEFICIT	$	7,755,321		$	4,304,230

	Three Months			Three Months			Nine Months			Nine Months
	Ended			Ended			Ended			Ended
	August 31, 2017			August 31, 2016			August 31, 2017			August 31, 2016

Revenues	$	3,277,655		$	17,028		$	3,305,644		$	241,053

Cost of Sales		3,117,150			9,388			3,132,266			135,364

Gross Profit		160,505			7,640			173,378			105,689

General, Selling & Administrative Expenses		(908,378	)		(502,659	)		(2,375,051	)		(1,755,774	)

Loss from Operations		(747,873	)		(495,019	)		(2,201,673	)		(1,650,085	)

Other Income (Expenses)
Interest Expense		(489,593	)		(79,269	)		(1,048,283	)		(351,353	)
Total Other Income (Expenses)		(489,593	)		(79,269	)		(1,048,283	)		(351,353	)

Net Loss	$	(1,237,466	)	$	(574,288	)	$	(3,249,956	)	$	(2,001,438	)

Net loss attributable to Trident		(1,228,122	)		(566,582	)		(3,220,559	)		(1,990,807	)
Net loss attributable to Non-Controlling Interests		(9,344	)		(7,706	)		(29,397	)		(10,631	)


Loss per share - Basic and diluted	$	(0.04	)	$	(0.02	)	$	(0.10	)	$	(0.07	)

Weighted average number of common
shares outstanding - Basic and diluted		31,000,000			31,000,000			31,000,000			30,596,364

	Number of Options		Weighted Average Exercise Price		Contractual Life in Years		Intrinsic Value

Outstanding - November 30, 2016		2,358,333	$	0.96		2.51

Exercisable - November 30, 2016		1,666,667	$	1.17		2.43

Granted		-0-			$	0.0

Exercised or Vested		-0-

Cancelled or Expired		333,333

Outstanding - August 31, 2017		2,025,000	$	0.96		1.68

Exercisable - August 31, 2017		2,025,000	$	0.96		1.68	$8,417

	Number of Warrants		Weighted Average Exercise Price		Contractual Life in Years			Intrinsic Value

Outstanding – November 30, 2016		225,000	$	1.35		2.21

Exercisable - November 30, 2016		-0-

Granted		-0-

Exercised or Vested		-0-

Cancelled or Expired		-0-

Outstanding – August 31, 2017		225,000	$	1.35		1.45	$	0

	Three Months Ended		Three Months Ended
	August 31, 2017		August 31, 2016

Revenues	$	3,277,655	$	17,028
Gross Profit	$	160,505	$	7,640
Operating Expenses	$	908,378	$	502,659
Other Expenses	$	489,593	$	79,269
Net Loss	$	1,237,466	$	574,288

	Nine Months Ended		Nine Months Ended
	August 31, 2017		August 31, 2016

Revenues	$	3,305,644	$	241,053
Gross Profit	$	173,378	$	105,689
Operating Expenses	$	2,375,051	$	1,755,774
Other Expenses	$	1,048,283	$	351,353
Net Loss	$	3,249,956	$	2,001,438

Balance Sheet Data:	August 31, 2017			August 31, 2016

Cash	$	4,380,378		$	4,484
Total assets	$	7,755,321		$	3,006,386
Total liabilities	$	11,053,311		$	4,736,704
Stockholders' (deficit)	$	(3,297,990	)	$	(1,730,318	)